4th World Congress on Interventional Therapies for Type 2 Diabetes (WCITD 2019)

4th World Congress on Interventional Therapies for Type 2 Diabetes (WCITD 2019) is organized by Kenes Group in partnership with the American Diabetes Association (ADA) and will be held from Apr 08 - 10, 2019 at New York Hilton Midtown, New York City, New York, United States of America.

Target Audience:
This activity is intended for physicians, nurses, and other health care professionals involved in the fields of Type 2 diabetes (T2D) and Endocrinology.

Accreditation:
Physician Continuing Medical Education:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 23.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credits Breakdown:
Monday, April 8, 2019 - 9 Credits
Tuesday, April 9, 2019 - 9.25 Credits
Wednesday, April 10, 2019 - 5.5 Credits

Continuing Nursing Education:
The maximum number of hours awarded for this Continuing Nursing Education activity is 23.7 contact hours.

Credits Breakdown:
Monday, April 8, 2019 - 9 Credits
Tuesday, April 9, 2019 - 9.2 Credits
Wednesday, April 10, 2019 - 5.5 Credits

Conference Description:
WCITD 2019 will convene clinicians, scientists, and policy makers to discuss the latest research findings on metabolic/bariatric surgery and novel interventional therapies for type 2 diabetes. The Organizing Committee is led by Francesco Rubino (Congress Director), together with Philip Schauer, David Cummings, Lee Kaplan, William Cefalu (Program Co-Chairs).

Conference Topics:
• Impact of bariatric/metabolic surgery on glycemic control
• Impact of bariatric/metabolic surgery on cardiometabolic risk
• Mechanisms of action of bariatric and metabolic surgery
• Randomized clinical trials comparing surgery vs medical treatment for diabetes
• Randomized clinical trials comparing surgical procedures head to head for the treatment of diabetes
• Novel technologies and gastrointestinal devices for diabetes
• Stigma and discrimination against people with diabetes and obesity
• Cost effectiveness of surgery as a treatment of diabetes
• Effects of bariatric/metabolic surgery on diabetes-related complications 
• Epidemiology and economic impact of diabetes
• Integration of pharmaceutical/surgical therapies and optimization of glcontrol post-surgery
• Intestinal glucose metabolism and nutrient sensing
• Role of bile acids in glucose homeostasis
• Role of gut microbiota in metabolism and in the pathophysiology of obesity and diabetes
• Role of the gastrointestinal tract in glucose metabolism
• Safety of bariatric/metabolic surgery

Educational Objectives:
After completing this activity, the participant should be better able to:

• Provide an update on clinical and biological evidence supporting surgical treatment of T2DM
• Present current ADA and International Guidelines (such as from the Diabetes Surgery Summit) regarding indications  for Metabolic Surgery to treat inadequately controlled T2DM
• Discuss uptake of metabolic/bariatric surgery in the USA and worldwide
• Identify barriers that prevent access to surgical and non-surgical therapies for diabetes and obesity around the world
• Develop a consensus on recommendations for changes in healthcare policies that ensure equitable access to surgical treatment of T2DM when indicated
• Provide an update of the latest research on device-based endoluminal approaches for the treatment of obesity and diabetes
• Provide an update of the latest research on the role of gastrointestinal mechanisms in the physiology and pathophysiology of glucose homeostasis
• Discuss the existing definition of biological and clinical remission of diabetes
• Develop a consensus on standardization of methods to evaluate and approve novel surgical procedures and other interventional therapies
• Discuss how widespread, out-dated views of body weight regulation contribute to reinforcing stigma and discrimination against people with obesity and related diseases
• Launch a broad educational initiative aimed at reducing the impact of stigma in the society and end discrimination against people with diabetes and obesity, in order to facilitate access to care and funding of research.

***Obesity Stigma Conference will be held on April 10, 2019

Time: 08:00 to 16:30

Price:
Early bird rate: USD 420.0

Speakers: Francesco Rubino, Philip Schauer, David Cummings, Lee Kaplan, William Cefalu